Cargando…

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients

AIM: To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC) patients. METHODS: Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge. A meta-analysis was conducted to determine the association between genetic polymorphisms a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Ji-Ye, Huang, Qiong, Zhao, Ying-Chun, Zhou, Hong-Hao, Liu, Zhao-Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383686/ https://www.ncbi.nlm.nih.gov/pubmed/22761669 http://dx.doi.org/10.1371/journal.pone.0038150

Ejemplares similares

Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis
por: Zhang, Ningning, et al.
Publicado: (2020)

Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients
por: Ye, Huan, et al.
Publicado: (2017)

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis
por: Tan, Li-Ming, et al.
Publicado: (2017)

Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients
por: Cui, Jia-Jia, et al.
Publicado: (2017)

Gene-gene and gene-environment interaction data for platinum-based chemotherapy in non-small cell lung cancer
por: Wang, Lei-Yun, et al.
Publicado: (2018)

Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients
por: Liu, Jun-Yan, et al.
Publicado: (2017)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy
por: Chen, Yi-Xin, et al.
Publicado: (2021)

Gene expression and single nucleotide polymorphism of ATP7B are associated with platinum-based chemotherapy response in non-small cell lung cancer patients
por: Li, Yue-Qin, et al.
Publicado: (2018)

The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Zou, Ting, et al.
Publicado: (2020)

A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survival
por: Wang, Liyan, et al.
Publicado: (2021)

Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy
por: Yuan, Zhengrong, et al.
Publicado: (2015)

Genetic Variants in DNA Mismatch Repair Pathway predict prognosis of Lung Cancer patients with receiving Platinum-Based Chemotherapy
por: Liu, Jun-Yan, et al.
Publicado: (2020)

Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients
por: Wu, Wenting, et al.
Publicado: (2012)

Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients
por: Qian, Chen-Yue, et al.
Publicado: (2016)

Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis
por: Chen, Juan, et al.
Publicado: (2016)

Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC
por: Peng, Wenpan, et al.
Publicado: (2021)

Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)
por: Li, Zhuang-hua, et al.
Publicado: (2012)

The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
por: Zhang, Jian-Wei, et al.
Publicado: (2014)

Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway
por: Mei, Ying, et al.
Publicado: (2018)

Wnt Signaling Pathway Pharmacogenetics in Non-Small Cell Lung Cancer
por: Stewart, David J., et al.
Publicado: (2014)

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
por: Nishio, Makoto, et al.
Publicado: (2021)

Predictive Value of XPD Polymorphisms on Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Qiu, Mantang, et al.
Publicado: (2013)

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)
por: Yang, Jiaying, et al.
Publicado: (2016)

Effect of Cinobufacini plus platinum-based chemotherapy regimen on the immune function of patients with non-small-cell lung cancer: A meta-analysis
por: Zhao, Yisheng, et al.
Publicado: (2023)

Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer
por: Lin, Sheng, et al.
Publicado: (2021)

Establishing a Prediction Model for the Efficacy of Platinum—Based Chemotherapy in NSCLC Based on a Two Cohorts GWAS Study
por: Xiao, Qi, et al.
Publicado: (2023)

Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis
por: Yang, Yanlong, et al.
Publicado: (2013)

XRCC3 Thr241Met Polymorphism and Clinical Outcomes of NSCLC Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
por: Shen, Xiao-yong, et al.
Publicado: (2013)

Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy
por: Xu, Shuyuan, et al.
Publicado: (2019)

The P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non–Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy()
por: Jia, Ming, et al.
Publicado: (2016)

Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC
por: Guo, Ao-Xiang, et al.
Publicado: (2020)

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients
por: Liu, Di, et al.
Publicado: (2017)

Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer
por: Zang, Hongjing, et al.
Publicado: (2017)

Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis
por: Chun, Sang Hoon, et al.
Publicado: (2011)

Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting
por: Soon, Yu Yang, et al.
Publicado: (2023)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy
por: Liu, Jia-Si, et al.
Publicado: (2023)

MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway
por: Fang, Chao, et al.
Publicado: (2017)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
por: Yang, Qian-Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_58lp4i6vni7lgrb13sp9m26gj6